First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients with Advanced Solid Tumors
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Pheon Therapeutics Ltd
The Sponsor will use tumor tissue samples along with other health information collected during the main study to conduct exploratory research in order to learn about the following: Why some people respond better to PHN-010. Why some people develop certain side effects caused by PHN-010. To better understand the disease being studied or other related diseases. To better understand the causes of diseases and how to diagnose, treat, or prevent them. To develop diagnostic tests.
Enrollment Form
This study is currently enrolling.